S. Korea's Celltrion Cancels Phase III Trials Of Lymphoma Generic
This article was originally published in PharmAsia News
Executive Summary
Celltrion, the South Korea-based drug maker the subject of widespread sell-out reports, has cancelled Phase III trials for a biosimilar of Roche's Rituxan (rituximab) for treating non-Hodgkins lymphoma.